EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: a nose-to-brain multitarget approach against glioblastoma.
Aline de Cristo Soares AlvesVladimir LavayenAmanda de Fraga DiasFranciele Aline BruinsmannJuliete Nathali SchollRodrigo CéFernanda VisioliAna Maria de Oliveira BattastiniSílvia Stanisçuaski GuterresFabrício FigueiróAdriana Raffin PohlmannPublished in: Nanomedicine (London, England) (2021)
Aim: To evaluate the antitumor efficacy of bevacizumab-functionalized nanocapsules in a rat glioblastoma model after the pretreatment with nanocapsules functionalized with a peptide-specific to the epidermal growth factor receptor variant III. Materials & methods: Nanocapsules were prepared, physicochemical characterized and intranasally administered to rats. Parameters such as tumor size, histopathological characteristics and infiltration of CD8+ T lymphocytes were evaluated. Results: The strategy of treatment resulted in a reduction of 87% in the tumor size compared with the control group and a higher infiltration of CD8+ T lymphocytes in tumoral tissue. Conclusion: The block of two different molecular targets using nose-to-brain delivery represents a new and promising approach against glioblastoma.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- white matter
- resting state
- advanced non small cell lung cancer
- oxidative stress
- functional connectivity
- cerebral ischemia
- combination therapy
- multiple sclerosis
- mass spectrometry
- high resolution
- subarachnoid hemorrhage
- simultaneous determination
- solid phase extraction